Male · 58 years
Non-smoker · BP controlled (~130–135/80–85 mmHg)
Established ASCVD (post-NSTEMI/PCI) automatically places this patient in the Very High Risk category, independent of calculated risk scores. SCORE2 and Pooled Cohort Equations are not required for risk categorisation; they confirm: estimated 10-year ASCVD risk >20%, SCORE2 fatal CVD risk >10%.
| Biomarker | Result | Unit | Very-High-Risk Target | Status | vs. Target |
|---|---|---|---|---|---|
| LDL-C | 2.1 mmol/L | (~81 mg/dL) | <1.4 mmol/L (ESC/EAS 2019) | ABOVE TARGET | +50% above goal |
| ApoB | 125 mg/dL | (1.25 g/L) | <65 mg/dL (ESC/EAS 2019) | CRITICAL | +92% above goal |
| Non-HDL-C | 4.5 mmol/L | (~174 mg/dL) | <2.2 mmol/L (ESC/EAS 2019) | CRITICAL | +105% above goal |
| Lp(a) | 190 nmol/L | (~85 mg/dL) | <125 nmol/L (EAS 2022) | VERY HIGH | Significantly elevated |
| Triglycerides | 2.6 mmol/L | (~230 mg/dL) | <1.7 mmol/L | ELEVATED | +53% above goal |
| HDL-C | 0.9 mmol/L | (~35 mg/dL) | >1.0 mmol/L (men) | LOW | Below threshold |
| Total Cholesterol | 5.4 mmol/L | (~209 mg/dL) | Context-dependent | ELEVATED | — |
LDL-C (2.1 mmol/L / 81 mg/dL) may create a false sense of reassurance — it is within a range some clinicians might consider "reasonable" for a secondary prevention patient on statin therapy. However, ApoB at 125 mg/dL is 92% above the very-high-risk target of 65 mg/dL.
This discordance is mechanistically explained: elevated triglycerides (2.6 mmol/L) and insulin resistance (HOMA-IR 4.5) drive hepatic overproduction of triglyceride-enriched VLDL particles, which are progressively remodeled into numerous small, cholesterol-depleted LDL particles. Each particle carries less cholesterol than average — keeping LDL-C lower than the true particle burden — while ApoB accurately counts all atherogenic particles regardless of their cholesterol content.
Clinical implication: Monitoring LDL-C alone in this patient would systematically underestimate atherogenic particle burden and residual cardiovascular risk. ApoB is the appropriate primary treatment target and monitoring metric.
| Biomarker | Result | Target / Optimal | Status | Clinical Implication |
|---|---|---|---|---|
| HbA1c | 7.6% | <7.0% (ADA/ESC 2023) | SUBOPTIMAL | Glycaemic control inadequate; CV outcome benefit from intensification |
| Fasting Glucose | 7.2 mmol/L (130 mg/dL) | <6.1 mmol/L | ELEVATED | Consistent with uncontrolled T2DM; drives atherogenic dyslipidaemia |
| Fasting Insulin | 14 mU/L (µIU/mL) | <10 mU/L (longevity optimal <5) | ELEVATED | Compensatory hyperinsulinaemia; drives TG elevation and small dense LDL |
| HOMA-IR | ≈ 4.5 | <1.9 (early IR); <1.0 optimal | SIGNIFICANT IR | Significant insulin resistance driving atherogenic dyslipidaemia phenotype |
Formula: HOMA-IR = (Fasting Insulin × Fasting Glucose) ÷ 405
Calculation: (14 × 130) ÷ 405 = 1,820 ÷ 405 = 4.49
A HOMA-IR of 4.5 is well above the threshold for significant insulin resistance (>2.9) and explains the atherogenic dyslipidaemia pattern seen in this patient: elevated TG (2.6 mmol/L), low HDL (0.9 mmol/L), and small dense LDL driving ApoB-LDL-C discordance.
The metabolic and lipid risk domains are deeply interconnected in this patient — insulin resistance is the upstream driver of the atherogenic particle burden.
Residual cardiovascular risk is evaluated across six biological domains. Each domain contributes independently to overall ASCVD risk and requires targeted management strategies.
ApoB 125 mg/dL (target <65 mg/dL) and Non-HDL-C 4.5 mmol/L (target <2.2 mmol/L) indicate a very high atherogenic particle burden despite statin therapy. Lp(a) 190 nmol/L adds a genetically-determined, largely statin-insensitive lipid risk layer. Triglyceride-rich lipoprotein remnant accumulation (TG 2.6 mmol/L) contributes additional atherogenic burden not captured by LDL-C. This patient's lipid residual risk is not minor — it is the dominant active risk domain requiring immediate therapeutic intensification.
hs-CRP has not been measured. In a patient with T2DM, obesity-associated metabolic syndrome features (low HDL, elevated TG), and post-MI status, elevated inflammatory markers are common and clinically relevant. Residual inflammatory risk — as demonstrated by the CANTOS and COLCOT trials — is independent of lipid risk and contributes meaningfully to recurrent events in post-MI patients. hs-CRP measurement is recommended as a priority missing investigation. If hs-CRP >2 mg/L, low-dose colchicine (0.5 mg/day) is a reasonable option to discuss — ESC 2024 Class IIa (Level A), on COLCOT and LoDoCo2 — tempered by the neutral 2024 CLEAR SYNERGY post-MI result, which makes patient selection and shared decision-making the sensible frame rather than a reflex add-on.
The patient is on aspirin post-PCI, which addresses standard antiplatelet requirements. However, Lp(a) at 190 nmol/L carries additional prothrombotic risk through structural resemblance of apo(a) to plasminogen, potentially impairing fibrinolysis. Dual antiplatelet therapy duration and need for P2Y12 inhibitor continuation should be reviewed per current ESC guidelines for post-ACS management. No additional thrombotic biomarkers (D-dimer, fibrinogen) documented — these are not routinely required but should be considered if clinical course suggests hypercoagulable state.
eGFR and urine ACR are not documented. This is a significant gap: T2DM of 6 years' duration, hypertension, and post-MI status all independently predispose to CKD development. Diabetic nephropathy affects approximately 40% of T2DM patients over time, and even mild CKD (eGFR 60–89 mL/min/1.73m²) amplifies cardiovascular risk substantially. KDIGO 2022 guidelines recommend annual eGFR and urine ACR monitoring in all T2DM patients. Additionally, SGLT2 inhibitor therapy (which this patient should be considered for CV benefit) has specific eGFR thresholds that must be checked before initiation.
At 58 years with established ASCVD, T2DM of 6 years, significant insulin resistance, and sustained atherogenic dyslipidaemia, cumulative vascular damage is expected to be substantial. No direct vascular ageing measurements are documented (coronary artery calcium score, carotid intima-media thickness, pulse wave velocity). A coronary artery calcium (CAC) score would provide additional prognostic information and may further guide treatment intensity decisions, though in this patient it would not change the very-high-risk classification or the need for maximal lipid-lowering.
LDL-C is 2.1 mmol/L vs. the ESC/EAS 2019 very-high-risk target of <1.4 mmol/L and >50% reduction from baseline. Current statin monotherapy is insufficient. Combination therapy (add ezetimibe ± PCSK9 inhibitor) is indicated.
ApoB 125 mg/dL vs. target <65 mg/dL for very-high-risk patients. In this patient, ApoB is the more clinically appropriate treatment monitoring target than LDL-C given the documented discordance driven by insulin resistance and elevated TG.
This patient has T2DM + established ASCVD — a combination for which SGLT2 inhibitors (empagliflozin, dapagliflozin, canagliflozin) and GLP-1 RAs (semaglutide, liraglutide) have demonstrated CV mortality and MACE reduction in landmark trials (EMPA-REG, CANVAS, DAPA-HF, LEADER, SUSTAIN-6). Current metformin monotherapy does not provide these benefits. This represents a significant guideline-adherence gap with direct survival implications.
In a post-MI patient with T2DM and metabolic-syndrome features, measuring hs-CRP is recommended as part of residual-risk assessment. A persistently elevated hs-CRP (>2 mg/L) is a recognised risk modifier (2025 ESC/EAS Focused Update) and identifies candidates for the anti-inflammatory pathway: low-dose colchicine 0.5 mg/day carries an ESC 2024 Class IIa (Level A) recommendation in atherosclerotic CAD (COLCOT −23% post-MI; LoDoCo2 −31% stable CAD). Note the large 2024 CLEAR SYNERGY (OASIS-9) post-MI trial was neutral, so colchicine is a considered option to weigh with the treating physician — not an automatic add-on.
Annual monitoring is mandatory per KDIGO 2022 and ADA 2024 in T2DM. Required before initiating SGLT2 inhibitor. CKD changes CV risk category and alters lipid and glycaemic management targets.
Father with MI at age 52 + very high Lp(a) (190 nmol/L) places this patient at the threshold for formal familial-hypercholesterolaemia scoring: calculate a Dutch Lipid Clinic Network or Simon Broome score, and offer cascade screening (including Lp(a)) to first-degree relatives.
Two interpretive cautions for this patient: (1) The mixed atherogenic pattern — high ApoB and high TG on a background of insulin resistance — may reflect familial combined hyperlipidaemia (FCH) rather than monogenic FH; the two carry different genetic and family-screening implications. (2) Very high Lp(a) contributes cholesterol that is measured within LDL-C ("pseudo-FH"), so an LDL-C-based FH score can read higher than the true LDL particle burden — account for the Lp(a) contribution when applying DLCN/Simon Broome criteria.
While CAC would not change this patient's very-high-risk classification, it would provide prognostic information on coronary atherosclerotic burden and may support future decision-making regarding intensity of therapy.
| Priority | Intervention | Rationale | Evidence | Expected Benefit |
|---|---|---|---|---|
| P1 — URGENT | Add ezetimibe 10 mg/day (if not already at maximum statin) |
LDL-C and ApoB above very-high-risk targets on statin monotherapy. Ezetimibe provides additive LDL-C reduction of 15–25% with well-established CV outcome benefit. | IMPROVE-IT Class I, Level B | ~15–25% further LDL-C reduction; ApoB reduction proportional |
| P1 — URGENT | Consider PCSK9 inhibitor (evolocumab or alirocumab) |
Despite statin + ezetimibe, LDL-C may still not reach <1.4 mmol/L target given ApoB discordance. PCSK9 inhibitors reduce LDL-C 50–60% additionally, reduce ApoB proportionally, and have demonstrated CV mortality reduction in high-risk post-ACS patients. | FOURIER ODYSSEY Class I, Level A | 50–60% additional LDL-C reduction; proven MACE and CV death reduction |
| P1 — URGENT | Add SGLT2 inhibitor (empagliflozin, dapagliflozin, or canagliflozin) |
T2DM + established ASCVD = Class I indication for SGLT2 inhibitor per ESC 2023 and ADA 2024. Provides: CV death/HF hospitalisation reduction, modest HbA1c improvement, renal protection. Check eGFR before initiation. | EMPA-REG CANVAS Class I, Level A | CV death reduction ~38% (EMPA-REG); HbA1c reduction ~0.5–1.0% |
| P2 — HIGH | Consider GLP-1 receptor agonist (semaglutide or liraglutide) |
If HbA1c remains >7.0% after SGLT2 inhibitor or if weight loss / triglyceride reduction is a priority, GLP-1 RA provides additional glycaemic benefit, CV outcome benefit, TG reduction (~15–30%), and HDL improvement. | LEADER SUSTAIN-6 Class I, Level A | CV death and stroke reduction; TG reduction; weight loss |
| P2 — HIGH | Icosapent ethyl 4g/day (if TG remains >1.5 mmol/L) |
TG 2.6 mmol/L after statin therapy. REDUCE-IT demonstrated 25% MACE reduction in high-CV-risk patients with elevated TG (≥1.5 mmol/L) treated with icosapent ethyl 4g/day, including in diabetes subgroup. | REDUCE-IT Class IIa, Level B | 25% MACE reduction; ~18% TG reduction; some ApoB benefit |
| P2 — HIGH | Measure hs-CRP (standard); if >2 mg/L, consider low-dose colchicine 0.5 mg/day | hs-CRP quantifies inflammatory residual risk (>2 mg/L = risk modifier, 2025 ESC/EAS Update). If elevated, colchicine 0.5 mg/day carries an ESC 2024 Class IIa (A) recommendation in atherosclerotic CAD (COLCOT −23% post-MI; LoDoCo2 −31% stable CAD). The neutral 2024 CLEAR SYNERGY post-MI trial makes this a selection-and-shared-decision option, not a reflex. | ESC 2024 CCS · IIa A COLCOT LoDoCo2 CLEAR SYNERGY | Measurable inflammatory-risk read; MACE benefit in trials, though not uniform |
| P3 — MONITOR | Lifestyle optimisation — structured programme | Mediterranean dietary pattern, 150–300 min/week moderate aerobic activity, resistance training 2×/week. Addresses insulin resistance, TG, HDL, and weight — all of which compound the atherogenic dyslipidaemia phenotype. | ESC/EAS 2019 ADA 2024 | HOMA-IR improvement; TG reduction; HDL improvement; weight loss |
| P3 — MONITOR | Lp(a) cascade family testing | Lp(a) is genetically determined. First-degree relatives (children, siblings) should be offered Lp(a) testing given level of 190 nmol/L + father's premature MI. | EAS 2022 Consensus | Early detection in relatives; opportunity for primary prevention |
The table above in execution order. This condenses the options for rapid review; class levels are shown, and every decision rests with the treating physician.
| Clinical Question | Guideline / Trial | Recommendation | Class / Level |
|---|---|---|---|
| LDL-C target in established ASCVD | ESC/EAS 2019 | LDL-C <1.4 mmol/L AND >50% reduction from baseline | Class I, Level A |
| ApoB target in very-high-risk | ESC/EAS 2019 | ApoB <65 mg/dL as secondary treatment target | Class I, Level B |
| Lp(a) threshold for CV risk | EAS Consensus 2022 | Lp(a) ≥125 nmol/L = major independent CV risk factor | EAS Expert Consensus |
| SGLT2 inhibitor in T2DM + ASCVD | ESC 2023 · ADA 2024 | Indicated regardless of HbA1c for CV benefit | Class I, Level A |
| GLP-1 RA in T2DM + ASCVD | ESC 2023 · ADA 2024 | Indicated for CV outcome benefit | Class I, Level A |
| Ezetimibe add-on to statin | ESC/EAS 2019 · IMPROVE-IT | Add ezetimibe if LDL-C target not achieved on statin | Class I, Level B |
| PCSK9 inhibitor in very-high-risk | ESC/EAS 2019 · FOURIER · ODYSSEY | Add if LDL-C not at target on statin ± ezetimibe | Class I, Level A |
| Colchicine post-MI / stable CAD | ESC 2024 CCS · COLCOT 2019 · LoDoCo2 2020 · CLEAR SYNERGY 2024 (neutral) | 0.5 mg/day — consider if hs-CRP >2 mg/L; weigh mixed post-MI data | Class IIa, Level A |
| Icosapent ethyl (TG ≥1.5 mmol/L) | REDUCE-IT 2018 | 4g/day in high-CV-risk with TG ≥1.5 mmol/L on statin | Class IIa, Level B |
| eGFR/ACR monitoring in T2DM | KDIGO 2022 · ADA 2024 | Annual monitoring mandatory | Class I |
Your cholesterol number may be misleading. Your LDL cholesterol on the blood test looks reasonable — but a marker called ApoB, which counts the actual number of harmful cholesterol-carrying particles in your blood, is nearly twice as high as it should be. This is because your diabetes and insulin resistance cause your liver to produce many more smaller particles than average. More particles means more risk, even when the cholesterol number looks acceptable.
You have an inherited risk factor that your current treatment cannot address. A protein called Lp(a) — which is determined almost entirely by your genes and not by diet or exercise — is very high in your blood. This adds risk of heart attack and stroke on top of your other risk factors, and it is not reduced by the statin medication you are currently taking. There are experimental treatments being tested in clinical trials, but none are yet approved.
Your diabetes is not yet well controlled, and this is increasing your heart risk. Your HbA1c (a 3-month average of your blood sugar) is 7.6%, which is above the recommended target of 7.0%. Your body is also producing much more insulin than it should to keep your blood sugar at this level — a pattern called insulin resistance that is linked to higher heart risk. There are newer diabetes medications that have been proven to reduce the chance of another heart attack.
Your fat levels in the blood are too high, and your protective cholesterol is too low. Your triglycerides (a type of fat in the blood) are elevated, and your HDL ("good" cholesterol) is below the healthy level. This combination is a recognised pattern in people with insulin resistance and increases heart risk beyond what your LDL alone would suggest.
Some important tests are missing. A measure of your kidney function (eGFR) and a urine test for kidney protein leakage (ACR) have not been documented in your recent results. These are important because diabetes can affect the kidneys, and kidney function affects how your heart risk is managed. Your doctor should check these regularly.
Your family history is important. Your father had a heart attack at 52 — this is considered "early." Combined with your very high Lp(a), it suggests that your children and siblings should have their Lp(a) checked, as elevated Lp(a) runs in families and can be detected and monitored long before problems develop.
Intensify lipid-lowering therapy urgently. LDL-C 2.1 mmol/L and ApoB 125 mg/dL — both substantially above ESC/EAS very-high-risk targets. Add ezetimibe 10 mg/day as first step. If targets not achieved within 3 months, initiate PCSK9 inhibitor (evolocumab or alirocumab). ApoB, not LDL-C, should be the primary monitoring target given documented discordance. ESC/EAS 2019 — Class I, Level A.
Initiate SGLT2 inhibitor — this is a Class I indication. T2DM + established ASCVD = mandatory SGLT2 inhibitor per ESC 2023 and ADA 2024, independent of HbA1c level. Check eGFR before initiation. Empagliflozin or dapagliflozin preferred for CV outcome evidence. Consider adding GLP-1 RA (semaglutide) if HbA1c remains >7.0% or weight loss/TG reduction is a priority. ESC 2023 — Class I, Level A.
Measure hs-CRP — inflammatory residual risk should be assessed, not assumed absent. In this metabolic phenotype (T2DM, elevated TG, low HDL, post-MI), elevated hs-CRP is common and is a recognised risk modifier (>2 mg/L, 2025 ESC/EAS Update). If elevated, low-dose colchicine 0.5 mg/day is an ESC 2024 Class IIa (A) option (COLCOT −23%, LoDoCo2 −31%), tempered by the neutral 2024 CLEAR SYNERGY post-MI trial — so patient selection and shared decision-making apply. Leaving inflammatory risk unmeasured forecloses that pathway entirely.
Lp(a) 190 nmol/L — document, monitor, and cascade-test. No approved Lp(a)-lowering therapy exists (Phase 3 trials underway). Current strategy: maximally lower LDL-C and ApoB to offset additive risk. Cascade Lp(a) testing in first-degree relatives (children >18 years, siblings). The combination of high Lp(a) + premature paternal MI warrants FH scoring (Dutch Lipid Clinic Network or Simon Broome criteria).
Order eGFR + urine ACR — renal assessment is overdue. 6 years of T2DM + hypertension + post-MI. Annual KDIGO-mandated screening not documented. CKD would: (a) further elevate CV risk category; (b) alter SGLT2 inhibitor dosing; (c) modify lipid management intensity. Albuminuria ≥30 mg/g would independently indicate SGLT2 inhibitor.
Consider icosapent ethyl 4g/day for triglyceride residual risk. TG 2.6 mmol/L on statin. REDUCE-IT demonstrated 25% MACE reduction in patients with TG ≥1.5 mmol/L + established CVD or high risk on statin therapy. Particularly relevant given the TG-driven atherogenic dyslipidaemia phenotype contributing to ApoB-LDL-C discordance. Class IIa, Level B.
Which report is this?
Every tier reads your own labs against longevity-optimal targets — not just "normal." The difference is how deep the panel goes and whether you get the physician-ready layer.
Built by a lipidologist, not a tech company.
Every report is interpretation calibrated to optimal targets by Dr. Tea Gamezardashvili, MD, PhD, FACC — preventive cardiologist & lipidologist. Educational, not a diagnosis; your physician decides.
Your report, your numbers
The sample above uses ApoB, Lp(a), insulin, and inflammation markers. Enter your own panel and get the same physician-grade interpretation, built by a lipidologist.
Get my report — from $29Standard ($49) includes ApoB & Lp(a) · one-time · interpretation, not diagnosis.
The first trial testing whether lowering Lp(a) actually prevents heart attacks — Lp(a)HORIZON — reports in 2026. When the results land, I'll send one plain-English summary: what it means, and what it doesn't. No hype, no spam.
One email when results land. Unsubscribe anytime.
This is an example report built from illustrative, de-identified numbers — not a real person's results. It's here to show you what your own report would look like.
A CardioIQ report helps you understand what your lab values mean, read against longevity-optimal targets rather than just "normal" ranges. It's educational information — not a medical diagnosis, and not a replacement for your doctor. It's built to make your next conversation with your physician a better one, never to substitute for it. Don't start, stop, or change any medication, supplement, or lifestyle plan based on a report alone — discuss your results and any decisions with your treating physician.
This report is generated by CardioIQ Clinical Intelligence Platform™ as a clinical decision support tool for qualified healthcare professionals. It does not constitute a medical diagnosis, does not prescribe treatment, and does not replace the clinical judgment of a licensed physician. All treatment decisions remain the exclusive responsibility of the treating healthcare professional. This document is de-identified and prepared for educational demonstration purposes only.